Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain
NCT ID: NCT05196386
Last Updated: 2025-09-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2020-08-06
2023-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The team at the local pain center recommends an average duration of 28 days for this type of pain. There is a full-time pharmacy intern in the rheumatology department.
The aim of this work is to evaluate the impact of a targeted pharmaceutical interview on the duration of the morphine treatment initiated during hospitalization.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.
NCT05905146
Dependence on Analgesics in Chronic Non-cancer Pain
NCT03346408
Understanding Persistent Pain Using a Decision Aid Tool in a Scottish Pharmacy Setting.
NCT05102578
Impact of a Pharmaceutical Interview at the Initiation of Opioid Treatment for Acute Non-cancer Pain
NCT07049796
Comparison of Standard Opioid Prescription Versus Prescription Guided by Pharmacogenetic Analysis in Patients With Non-cancerous Chronic Pain.
NCT03498014
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient with targeted pharmaceutical interview
Specific information about treatment delivered by pharmacist
Admission conciliation interview
Previous treatment conciliation at hospital admission
Discharge conciliation interview
Allocated treatment during hospital stay
Targeted pharmaceutical interview
Specific information about treatment delivered by pharmacist
Patient without targeted pharmaceutical interview
No Specific information about treatment delivered by pharmacist
Admission conciliation interview
Previous treatment conciliation at hospital admission
Discharge conciliation interview
Allocated treatment during hospital stay
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Admission conciliation interview
Previous treatment conciliation at hospital admission
Discharge conciliation interview
Allocated treatment during hospital stay
Targeted pharmaceutical interview
Specific information about treatment delivered by pharmacist
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalization in the rheumatology department
* Patient with acute non-traumatic musculoskeletal disease
* Patient not taking grade III opioid treatment
* Patient affiliated to a social security scheme
* Patient having read and understood the information letter and signed the consent form
* Patient present on a day which the pharmacy intern is present
Exclusion Criteria
* Patient does not understand French
* Patient with Current or past opioid addiction
* Person deprived of liberty by administrative or judicial decision
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Rouen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olivier VITTECOQ, Pr
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Rouen
Remi VARIN, Pr
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Rouen
Catherine CHENAILLER, Dr
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Rouen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rouen University Hospital
Rouen, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019/0025/HP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.